In the same study, weight loss statistics showed reductions of 13.7% and 3.2% from baseline, with an estimated 10.5% greater weight loss with semaglutide. Some of the news isnt surprising: Obesity is a major risk factor for knee OA, and since semaglutide promotes weight loss by regulating appetite and blood sugar levels, its potential to reduce pressure on your knee joints is fairly well understood
slowing gastric emptying
Zepbound, however, is supplied in vial form rather than pens, which adds a layer of complexity for patients self-administering the medication
The development program runs from Phase 1b through three completed Phase 3 readouts, with several more ongoing
Arrange a routine appointment with your GP or diabetes nurse if: Injection site reactions persist beyond one week or worsen progressively You develop a mild rash that does not resolve within a few days Skin changes cause concern or uncertainty about continuing treatment You experience persistent itching without visible rash When consulting your healthcare provider, provide comprehensive information including when the skin changes began, their location and appearance, any associated symptoms, and whether you have started any other new medications or products